Key Inclusion Criteria:

          -  DLBCL, follicular lymphoma (FL), or marginal zone lymphoma (MZL) expressing CD20 by
             immunohistochemistry (IHC) or flow cytometry, relapsed/refractory (R/R) to at least 2
             prior lines of therapy. Prior autologous hematopoietic cell transplantation and
             individuals with transformed lymphomas are permitted. Individuals must be at least 3
             months out from prior autologous hematopoietic cell transplantation. Individuals with
             indolent lymphomas must be candidates for systemic treatment in the judgment of the
             treating physician.

          -  In the DLBCL Expansion part: Individuals must have de novo or transformed DLBCL
             expressing CD20 by IHC or flow cytometry, that is relapsed or refractory to at least 2
             prior lines of therapy. Prior autologous hematopoietic cell transplantation and
             individuals with transformed lymphomas are permitted.

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2.

          -  For the DLBCL expansion cohort, disease must be measurable for response per Lugano
             criteria. For all other cohorts, disease must be measurable or assessable for response
             per Lugano criteria.

          -  Exhibit acceptable hematopoietic, liver, renal, and coagulation function as assessed
             by laboratory tests.

        Key Exclusion Criteria:

          -  Individuals with active brain metastases (Individuals with stable treated central
             nervous system (CNS) lesions who are off corticosteroid therapy for at least 3 weeks
             are not considered active.

          -  Individuals with Burkitt's lymphoma.

          -  Prior treatment with a chimeric antigen receptor (CAR) T-cell therapy.

          -  Prior allogeneic stem cell transplant.

          -  Previous anticancer therapy including chemotherapy, hormonal therapy, and
             investigational agents within 3 weeks or at least 4 half-lives (up to a maximum of 4
             weeks), whichever is longer, prior to first dose of study drug.

          -  Known active or chronic hepatitis B or C infection or human immunodeficiency virus.

          -  Prior treatment with CD47 or signal regulatory protein alpha (SIRPα)-targeting agents.

          -  Hypersensitivity to the active substance, to murine proteins, or to any of the other
             excipients of rituximab

          -  Significant medical diseases or conditions, as assessed by the Investigator and
             Sponsor, that would substantially increase the risk:benefit ratio of participating in
             the study. This includes, but is not limited to, acute myocardial infarction within
             the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active
             infections, severely immunocompromised state, and congestive heart failure New York
             Heart Association Classes II to IV.

          -  Rituximab-containing cohorts only: Receipt of live/attenuated vaccines within 30 days
             of rituximab dosing

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.